Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director · CEO and President | June 29, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protara Therapeutics, Inc.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 691,832 |
Ending reported balance
After 2026-06-30 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-06-29 · Exercise / conversion · Acquired 215,687 · Balance 937,519 Row 2 · 2026-06-29 · Sale · Disposed 215,687 · Balance 721,832 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 to $4.14, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2026-06-30 · Gift · Disposed 14,000 · Balance 707,832 Row 4 · 2026-06-30 · Gift · Disposed 7,000 · Balance 700,832 Row 5 · 2026-06-30 · Gift · Disposed 4,000 · Balance 696,832 Row 6 · 2026-06-30 · Gift · Disposed 5,000 · Balance 691,832 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2034-01-18 | Direct | 141,313 |
Reported balance
After 2026-06-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-06-29 · Exercise / conversion · Disposed 215,687 · Balance 141,313 F4: 25% of the shares underlying the option vested on January 19, 2025 and the remaining shares have vested or will vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's continuous service with the Issuer as of each such date. |
| Common StockSEC Table I · non-derivative | IndirectThe Samhold Family Trust | 300,000 |
Reported balance
Holding disclosure · report date 2026-06-29 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 300,000 F2: The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest, and this report should not be deemed an admission that the Reporting Person or any other person named herein is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F3: The reported securities held by the Samhold Family Trust were inadvertently included under the Reporting Person's direct holdings in the prior Form 4 filings filed by the Reporting Person on January 21, 2026, January 22, 2026 and January 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 to $4.14, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest, and this report should not be deemed an admission that the Reporting Person or any other person named herein is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3: The reported securities held by the Samhold Family Trust were inadvertently included under the Reporting Person's direct holdings in the prior Form 4 filings filed by the Reporting Person on January 21, 2026, January 22, 2026 and January 27, 2026.
F4: 25% of the shares underlying the option vested on January 19, 2025 and the remaining shares have vested or will vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's continuous service with the Issuer as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-074238 · marketforms-73501.xml · nonDerivative · entry 6 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 691,832 Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-074238 · marketforms-73501.xml · nonDerivative · entry 5 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 696,832 Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-074238 · marketforms-73501.xml · nonDerivative · entry 4 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,832 Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-074238 · marketforms-73501.xml · nonDerivative · entry 3 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707,832 Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Exercise / conversionStock Option (Right to Buy) · Derivative | 215,687 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001213900-26-074238 · marketforms-73501.xml · derivative · entry 8 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,313 Underlying: Common Stock · 215,687 shares Expires 2034-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 19, 2025 and the remaining shares have vested or will vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock | 215,687 | $4.09 | $882,159.83 |
DisclosureSEC source: 0001213900-26-074238 · marketforms-73501.xml · nonDerivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,832 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 to $4.14, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Exercise / conversionCommon Stock | 215,687 | $1.91 | $411,962.17 |
DisclosureSEC source: 0001213900-26-074238 · marketforms-73501.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 937,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 8,732 | $6.67 | $58,242.44 |
DisclosureSEC source: 0001213900-26-008224 · marketforms-71934.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,021,832 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:30 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 16,322 | $5.60 | $91,403.20 |
DisclosureSEC source: 0001213900-26-006711 · marketforms-71772.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,030,564 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 19, 2023 and January 19, 2024. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:36 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 524,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001213900-26-006226 · marketforms-71894.xml · derivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,000 Underlying: Common Stock · 524,000 shares Expires 2036-01-15 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:36 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 87,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-006226 · marketforms-71894.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,046,886 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 3,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-059655 · marketforms-69999.xml · nonDerivative · entry 4 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 959,886 Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-059655 · marketforms-69999.xml · nonDerivative · entry 3 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 963,253 Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 3,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-059655 · marketforms-69999.xml · nonDerivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 973,453 Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 1,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-059655 · marketforms-69999.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 976,853 Read SEC document |
| June 24, 2025 Filed Jul 7, 2025 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061772 · marketforms-70060.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 659,886 F1 · ownership.direct: On June 24, 2025, the reporting person transferred 300,000 shares of common stock to The Samhold Family Trust for no consideration. Members of the reporting person's immediate family are the sole beneficiaries of the trust and a member of the reporting person's immediate family serves as a trustee thereof. The reporting person remains the beneficial owner of the securities held by the trust. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 387,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001213900-25-007533 · marketforms-67930.xml · derivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,000 Underlying: Common Stock · 387,000 shares Expires 2035-01-23 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 24, 2025 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-007533 · marketforms-67930.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,022 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 24, 2025. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 15,469 | $4.76 | $73,632.44 |
DisclosureSEC source: 0001213900-25-005962 · marketforms-67893.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 913,553 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 19, 2023 and January 19, 2024. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:20 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 6,479 | $6.14 | $39,781.06 |
DisclosureSEC source: 0001213900-25-001648 · marketforms-67735.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929,022 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-074514 · marketforms-66787.xml · nonDerivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 935,501 Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 5,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-074514 · marketforms-66787.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 938,801 Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 357,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001213900-24-005725 · marketforms-64334.xml · derivative · entry 3 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,000 Underlying: Common Stock · 357,000 shares Expires 2034-01-18 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2024 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 7,803 | $1.91 | $14,903.73 |
DisclosureSEC source: 0001213900-24-005725 · marketforms-64334.xml · nonDerivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944,064 F3 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2023. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 59,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-005725 · marketforms-64334.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 951,867 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2024. Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 5,746 | $2.39 | $13,732.94 |
DisclosureSEC source: 0001213900-24-003336 · marketforms-64052.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 892,867 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2020. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:30 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 5,840 | $2.17 | $12,672.80 |
DisclosureSEC source: 0001213900-24-001541 · marketforms-63998.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 898,613 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 23:26 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 7,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-052231 · ownership.xml · nonDerivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 904,453 Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 23:26 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 1,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-052231 · ownership.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911,873 Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 307,500 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001213900-23-004081 · ownership.xml · derivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 307,500 shares Expires 2033-01-18 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2023 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 51,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-004081 · ownership.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918,282 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2023. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:03 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 5,855 | $3.00 | $17,565.00 |
DisclosureSEC source: 0001213900-23-002261 · ownership.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,982 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2020. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:25 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 6,604 | $2.80 | $18,491.20 |
DisclosureSEC source: 0001213900-23-000854 · ownership.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872,837 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 21:49 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | PurchaseCommon Stock | 9,065 | $3.84 | $34,809.60 |
DisclosureSEC source: 0001213900-22-048179 · ownership.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879,441 F1 · price: The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.66 to $3.93, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 27, 2022 Filed Feb 10, 2023 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 4,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-010283 · ownership.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 913,763 Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 22:18 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 5,080 | $6.27 | $31,851.60 |
DisclosureSEC source: 0001209191-22-003088 · doc4.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872,425 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2020. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:36 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 253,500 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001209191-22-001719 · doc4.xml · derivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,500 Underlying: Common Stock · 253,500 shares Expires 2032-01-02 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 3, 2022 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:36 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 42,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001719 · doc4.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,505 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 3, 2022. Read SEC document |
| June 29, 2021 Filed Feb 11, 2022 21:49 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 513 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008912 · doc5.xml · nonDerivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,376 Read SEC document |
| June 29, 2021 Filed Feb 11, 2022 21:49 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GiftCommon Stock | 1,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008912 · doc5.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,889 Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 20:03 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 202,000 | $0.00 Strike: $19.82 | $0.00 |
DisclosureSEC source: 0001209191-21-004651 · doc4.xml · derivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,000 Underlying: Common Stock · 202,000 shares Expires 2031-01-18 F1 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 22:16 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 5,069 | $21.16 | $107,260.04 |
DisclosureSEC source: 0001209191-21-003445 · doc4.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,205 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 10, 2020. Read SEC document |
| July 10, 2020 Filed Jul 13, 2020 18:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 111,250 | $0.00 Strike: $27.42 | $0.00 |
DisclosureSEC source: 0001209191-20-042242 · doc4.xml · derivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,250 Underlying: Common Stock · 111,250 shares Expires 2030-07-09 F1 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 10, 2020 and 1/48th of the shares vesting monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 23:57 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 111,250 | $0.00 Strike: $31.50 | $0.00 |
DisclosureSEC source: 0001209191-20-003223 · doc4.xml · derivative · entry 3 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,250 Underlying: Common Stock · 111,250 shares Expires 2030-01-09 F4 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 10, 2020 and 1/48th of the shares vesting monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 23:57 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003223 · doc4.xml · nonDerivative · entry 2 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,274 F3 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of Issuer's common stock. 25% of the shares vest on each one-year anniversary of January 10, 2020. Read SEC document |
| January 10, 2020 Filed Feb 18, 2020 21:30 UTC Amendment | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 111,250 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010143 · doc4a.xml · derivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,250 Underlying: Common Stock · 111,250 shares Expires 2030-01-09 F1 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 10, 2020 and 1/48th of the shares vesting monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:57 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 790,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-003223 · doc4.xml · nonDerivative · entry 1 Shefferman Jesse · CIK 0001799167 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,274 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F2 · price: These shares were received in exchange for i) 4,000,000 shares of ArTara Sub Common Stock; and ii) 142,857 shares of ArTara Sub Exchangeable Common Stock, in connection with the Merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.